AGMB — AgomAb Therapeutics N.V. American Depositary Shares stock price, charts and financials

QT64AgomAb Therapeutics N.V. American Depositary Shares

Latest market price

14.73

+1.21+8.95%

Overview Short InterestFilings

AGMBQT64AgomAb Therapeutics N.V. American Depositary Shares·NASDAQ

Overview Short InterestFilings

14.73+8.95%

Loading chart...

Screen all →

OCUL+2.26%$8.59 MESO+2.28%$14.80 AUPH+2.47%$14.93 TYRA+1.53%$32.53 URGN+3.45%$39.92 IOVA+0.93%$4.36 STOK+7.14%$31.67 TSHA+7.27%$6.20

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	49.25M	Perf Week	17.46%

Market Cap	725.42M	Forward P/E	-	EPS next Y	-2.46	Insider Trans	-	Shs Float	36.26M	Perf Month	8.95%

Enterprise Value	589.42M	PEG	-	EPS next Q	-0.44	Inst Own	-	Short Float	3.42%	Perf Quarter	21.64%

Income	-68.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	11.02	Perf Half Y	-

Sales	0.00	P/B	4.71	EPS next Y	-16.65%	ROA	-39.09%	Short Interest	1.24M	Perf YTD	0.20%

Book/sh	3.13	P/C	5.30	EPS next 5Y	-	ROE	-45.90%	52W High	17.82 -17.34%	Perf Year	-

Cash/sh	2.78	P/FCF	-	EPS past 3/5Y	-	ROIC	-43.44%	52W Low	8.75 68.34%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	8.33% 8.03%	Perf 5Y	-

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-	Oper. Margin	0.00%	ATR (14)	1.15	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	6.52	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	65.06	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	6.52	EPS Q/Q	-	SMA20	16.80%	Beta	1.82	Target Price	35.00

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-	SMA50	22.12%	Rel Volume	0.94	Prev Close	13.52

Employees	62	LT Debt/Eq	0.01	Earnings	Sep 02	SMA200	18.77%	Avg Volume	93.03K	Price	14.73

IPO Date	Feb 06, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	-8740.98% -	Net Debt/EBITDA	1.37	Volume	87,369	Change	8.95%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jun-22-26	Initiated	H.C	Buy	$35

Latest News

Jul-23-26

Jul-23-2610:13AM

B. Riley Securities Initiates Coverage On AgomAb Therapeutics with Buy Rating, Announces Price Target of $34Benzinga

Jul-06-26

Jul-06-2608:00AM

Rare Stock Picks In June 2026 - From 19 Discerning AnalystsSeekingAlpha

Jun-23-26

Jun-23-2604:13PM

Agomab Therapeutics Aligns With FDA On Design Of Phase 2b NOV-ERA Study With OntunisertibBenzinga

Jun-22-26

Jun-22-2612:08PM

This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For MondayBenzinga

08:37AM

This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For MondayBenzinga

07:01AM

HC Wainwright & Co. Initiates Coverage On AgomAb Therapeutics with Buy Rating, Announces Price Target of $35Benzinga

Company

AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022
Total Revenue	0	0	0	0
Cost of Goods Sold Incl. D&A	0	0	0	0
Gross Profit	0	0	0	0
Selling, General and Administrative Excl. Other	14	11	6	5
Research and Development	55	43	28	20
Other Operating Expense	-2	-2	0	-1
Operating Income	-67	-52	-34	-24
Interest Expense	0	0	0	0
Unusual Expense	—	—	—	—
Non-Operating Income (Expense)	-4	2	21	12
Net Income Before Taxes	-71	-50	-13	-11
Income Taxes	-1	0	-1	-3
Consolidated Net Income	-68	-50	-12	-9
Net Income From Continuing Operations	-68	-50	-12	-9
Net Income	-68	-50	-12	-9
EPS (Recurring)	-1.39	-1.36	-0.34	-0.23
EPS (Basic, Before Extraordinaries)	-1.39	-1.36	-0.34	-0.23
EPS (Diluted)	-1.39	-1.36	-0.34	-0.23
EBITDA	-70	-50	-13	-11
Other After Tax Adjustments	—	—	—	—
Stock Option Compensation Expense	—	—	—	—
Price To Earnings Ratio	—	—	—	—
Price To Sales Ratio	—	—	—	—
Gross Margin	—	—	—	—
Operating Margin	—	—	—	—
Net Margin	—	—	—	—
Shares Outstanding	49	36	36	36
Market Capitalization	—	—	—	—
Operating Lease Expense	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.